Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients

• Published in: The journal of clinical endocrinology and metabolism Vol. 107; no. 5; pp. 1368 - 1374
• Main Authors: Bertelsen, Bjørn-Erik, Viste, Kristin, Helland, Thomas, Hagland, Magnus, Søiland, Håvard, Geisler, Jürgen, Lende, Tone Hoel, Lønning, Per Eystein, Sagen, Jørn V, Mellgren, Gunnar, Almås, Bjørg
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.05.2022
• Subjects: 17β-Estradiol; Anastrozole; Anastrozole - therapeutic use; Aromatase; Aromatase Inhibitors - pharmacology; Aromatase Inhibitors - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Cancer; Cancer patients; Care and treatment; Clinical; Drug therapy; Estradiol; Estrogens; Estrogens - therapeutic use; Estrone; Female; Humans; Ionization; Letrozole; Liquid chromatography; Mass spectrometry; Mass spectroscopy; Nitriles - pharmacology; Post-menopause; Postmenopausal women; Postmenopause; Quality control; Serum levels; Tandem Mass Spectrometry; Norway; letrozole; breast cancer; exemestane; aromatase inhibitors; anastrozole; estradiol

Abstract Context Currently there are no assays that can simultaneously quantify serum levels of the third-generation aromatase inhibitors (AIs): letrozole, anastrozole, and exemestane, and the ultra-low levels of estrogens in postmenopausal breast cancer patients on AI treatment. Such measurements m...